Pre-surgery therapy to preserve the rectum for advanced low rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy and radiation before surgery for people with locally advanced low rectal cancer. The goal is to shrink the tumor enough to avoid removing the anus and keep the rectum intact.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of rectal cancer called adenocarcinoma that is mismatch repair proficient (pMMR) or microsatellite stable (MSS).
- Your tumor is stage cT2-T4 and/or has spread to nearby lymph nodes but not to distant organs (M0).
- The tumor is located within about 3 inches (8 cm) from the anal opening, or your surgeon says it's too low to save the anus with standard surgery.
- You want to try to save your anus and are willing to stay in close follow-up for at least 2 years after treatment.
- You are willing and able to have surgery if needed, and your surgeon agrees it's safe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines chemotherapy, immunotherapy, and radiation before surgery for patients with middle or low rectal cancer. The goal is to shrink the tumor enough to avoid removing the anus, preserving bowel function.
This trial tests a new approach for people with locally advanced low rectal cancer that is pMMR type. You would receive a combination of an immunotherapy drug (anti-PD-1) with chemotherapy (FOLFOXIRI) and radiation before any surgery, to try to shrink the tumor as much as possible.
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
This Phase 2 trial tests a “total neoadjuvant” treatment plan (medicine given before surgery) that may help some people avoid or reduce surgery for very low rectal cancer. It aims to improve the chance of keeping more normal function while still treating the cancer safely.
This trial tests if adding immunotherapy and an anti-angiogenesis drug to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer that has not spread. You may benefit if your tumor is in the lower part of the rectum and you haven't had prior cancer treatment.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
Hear when a new Colorectal Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.